nodes	percent_of_prediction	percent_of_DWPC	metapath
Riluzole—ABCG2—Carboplatin—esophageal cancer	0.206	0.415	CbGbCtD
Riluzole—ABCG2—Cisplatin—esophageal cancer	0.176	0.355	CbGbCtD
Riluzole—ABCG2—Methotrexate—esophageal cancer	0.114	0.23	CbGbCtD
Riluzole—Hypokalaemia—Capecitabine—esophageal cancer	0.000614	0.00207	CcSEcCtD
Riluzole—Breast disorder—Capecitabine—esophageal cancer	0.00061	0.00205	CcSEcCtD
Riluzole—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000607	0.00205	CcSEcCtD
Riluzole—Sepsis—Methotrexate—esophageal cancer	0.0006	0.00202	CcSEcCtD
Riluzole—Gastritis—Capecitabine—esophageal cancer	0.000597	0.00201	CcSEcCtD
Riluzole—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000595	0.00201	CcSEcCtD
Riluzole—Muscular weakness—Capecitabine—esophageal cancer	0.000595	0.00201	CcSEcCtD
Riluzole—Eye disorder—Cisplatin—esophageal cancer	0.000592	0.00199	CcSEcCtD
Riluzole—Lymphadenopathy—Methotrexate—esophageal cancer	0.000589	0.00198	CcSEcCtD
Riluzole—Cardiac disorder—Cisplatin—esophageal cancer	0.000587	0.00198	CcSEcCtD
Riluzole—Abdominal distension—Capecitabine—esophageal cancer	0.000587	0.00198	CcSEcCtD
Riluzole—Influenza—Capecitabine—esophageal cancer	0.000583	0.00196	CcSEcCtD
Riluzole—Dysphagia—Capecitabine—esophageal cancer	0.000583	0.00196	CcSEcCtD
Riluzole—Asthma—Capecitabine—esophageal cancer	0.000583	0.00196	CcSEcCtD
Riluzole—Diabetes mellitus—Methotrexate—esophageal cancer	0.000577	0.00195	CcSEcCtD
Riluzole—Photosensitivity—Methotrexate—esophageal cancer	0.000572	0.00193	CcSEcCtD
Riluzole—Immune system disorder—Cisplatin—esophageal cancer	0.000572	0.00193	CcSEcCtD
Riluzole—Mediastinal disorder—Cisplatin—esophageal cancer	0.000571	0.00192	CcSEcCtD
Riluzole—Angina pectoris—Capecitabine—esophageal cancer	0.000568	0.00191	CcSEcCtD
Riluzole—Arrhythmia—Cisplatin—esophageal cancer	0.000565	0.00191	CcSEcCtD
Riluzole—Bronchitis—Capecitabine—esophageal cancer	0.000561	0.00189	CcSEcCtD
Riluzole—Alopecia—Cisplatin—esophageal cancer	0.000559	0.00189	CcSEcCtD
Riluzole—Abdominal discomfort—Capecitabine—esophageal cancer	0.000559	0.00188	CcSEcCtD
Riluzole—Pancytopenia—Capecitabine—esophageal cancer	0.000554	0.00187	CcSEcCtD
Riluzole—Malnutrition—Cisplatin—esophageal cancer	0.000551	0.00186	CcSEcCtD
Riluzole—Dysuria—Capecitabine—esophageal cancer	0.000545	0.00184	CcSEcCtD
Riluzole—Neutropenia—Capecitabine—esophageal cancer	0.000545	0.00184	CcSEcCtD
Riluzole—Flatulence—Cisplatin—esophageal cancer	0.000543	0.00183	CcSEcCtD
Riluzole—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000532	0.00179	CcSEcCtD
Riluzole—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000532	0.00179	CcSEcCtD
Riluzole—Weight increased—Capecitabine—esophageal cancer	0.000531	0.00179	CcSEcCtD
Riluzole—Muscle spasms—Cisplatin—esophageal cancer	0.00053	0.00179	CcSEcCtD
Riluzole—Weight decreased—Capecitabine—esophageal cancer	0.000527	0.00178	CcSEcCtD
Riluzole—Pneumonia—Capecitabine—esophageal cancer	0.000523	0.00176	CcSEcCtD
Riluzole—Infestation NOS—Capecitabine—esophageal cancer	0.00052	0.00175	CcSEcCtD
Riluzole—Infestation—Capecitabine—esophageal cancer	0.00052	0.00175	CcSEcCtD
Riluzole—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000519	0.00175	CcSEcCtD
Riluzole—Depression—Capecitabine—esophageal cancer	0.000518	0.00175	CcSEcCtD
Riluzole—Tremor—Cisplatin—esophageal cancer	0.000516	0.00174	CcSEcCtD
Riluzole—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000512	0.00173	CcSEcCtD
Riluzole—Ill-defined disorder—Cisplatin—esophageal cancer	0.000511	0.00172	CcSEcCtD
Riluzole—Myocardial infarction—Capecitabine—esophageal cancer	0.00051	0.00172	CcSEcCtD
Riluzole—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00051	0.00172	CcSEcCtD
Riluzole—Anaemia—Cisplatin—esophageal cancer	0.000509	0.00172	CcSEcCtD
Riluzole—Jaundice—Capecitabine—esophageal cancer	0.000507	0.00171	CcSEcCtD
Riluzole—Stomatitis—Capecitabine—esophageal cancer	0.000507	0.00171	CcSEcCtD
Riluzole—Urinary tract infection—Capecitabine—esophageal cancer	0.000505	0.0017	CcSEcCtD
Riluzole—Osteoarthritis—Methotrexate—esophageal cancer	0.000502	0.00169	CcSEcCtD
Riluzole—Malaise—Cisplatin—esophageal cancer	0.000497	0.00167	CcSEcCtD
Riluzole—Haematuria—Capecitabine—esophageal cancer	0.000496	0.00167	CcSEcCtD
Riluzole—Leukopenia—Cisplatin—esophageal cancer	0.000493	0.00166	CcSEcCtD
Riluzole—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000492	0.00166	CcSEcCtD
Riluzole—Epistaxis—Capecitabine—esophageal cancer	0.00049	0.00165	CcSEcCtD
Riluzole—Agranulocytosis—Capecitabine—esophageal cancer	0.000485	0.00163	CcSEcCtD
Riluzole—Convulsion—Cisplatin—esophageal cancer	0.000477	0.00161	CcSEcCtD
Riluzole—Mood swings—Methotrexate—esophageal cancer	0.000476	0.0016	CcSEcCtD
Riluzole—Bradycardia—Capecitabine—esophageal cancer	0.000475	0.0016	CcSEcCtD
Riluzole—Ataxia—Methotrexate—esophageal cancer	0.000472	0.00159	CcSEcCtD
Riluzole—Myalgia—Cisplatin—esophageal cancer	0.000469	0.00158	CcSEcCtD
Riluzole—Haemoglobin—Capecitabine—esophageal cancer	0.000469	0.00158	CcSEcCtD
Riluzole—Rhinitis—Capecitabine—esophageal cancer	0.000468	0.00158	CcSEcCtD
Riluzole—Anxiety—Cisplatin—esophageal cancer	0.000468	0.00158	CcSEcCtD
Riluzole—Hepatitis—Capecitabine—esophageal cancer	0.000467	0.00157	CcSEcCtD
Riluzole—Haemorrhage—Capecitabine—esophageal cancer	0.000467	0.00157	CcSEcCtD
Riluzole—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000466	0.00157	CcSEcCtD
Riluzole—Hypoaesthesia—Capecitabine—esophageal cancer	0.000464	0.00156	CcSEcCtD
Riluzole—Liver function test abnormal—Methotrexate—esophageal cancer	0.000464	0.00156	CcSEcCtD
Riluzole—Discomfort—Cisplatin—esophageal cancer	0.000464	0.00156	CcSEcCtD
Riluzole—Pharyngitis—Capecitabine—esophageal cancer	0.000463	0.00156	CcSEcCtD
Riluzole—Urinary tract disorder—Capecitabine—esophageal cancer	0.000461	0.00155	CcSEcCtD
Riluzole—Oedema peripheral—Capecitabine—esophageal cancer	0.00046	0.00155	CcSEcCtD
Riluzole—Connective tissue disorder—Capecitabine—esophageal cancer	0.000459	0.00155	CcSEcCtD
Riluzole—Urethral disorder—Capecitabine—esophageal cancer	0.000457	0.00154	CcSEcCtD
Riluzole—Breast disorder—Methotrexate—esophageal cancer	0.000454	0.00153	CcSEcCtD
Riluzole—CYP1A1—Biological oxidations—ADH7—esophageal cancer	0.000453	0.00218	CbGpPWpGaD
Riluzole—Oedema—Cisplatin—esophageal cancer	0.00045	0.00152	CcSEcCtD
Riluzole—Anaphylactic shock—Cisplatin—esophageal cancer	0.00045	0.00152	CcSEcCtD
Riluzole—Infection—Cisplatin—esophageal cancer	0.000447	0.00151	CcSEcCtD
Riluzole—SLC7A11—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000445	0.00215	CbGpPWpGaD
Riluzole—CYP1A2—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000443	0.00214	CbGpPWpGaD
Riluzole—Erythema multiforme—Capecitabine—esophageal cancer	0.000441	0.00149	CcSEcCtD
Riluzole—Nervous system disorder—Cisplatin—esophageal cancer	0.000441	0.00149	CcSEcCtD
Riluzole—Thrombocytopenia—Cisplatin—esophageal cancer	0.00044	0.00148	CcSEcCtD
Riluzole—Tachycardia—Cisplatin—esophageal cancer	0.000439	0.00148	CcSEcCtD
Riluzole—Skin disorder—Cisplatin—esophageal cancer	0.000437	0.00147	CcSEcCtD
Riluzole—Eye disorder—Capecitabine—esophageal cancer	0.000436	0.00147	CcSEcCtD
Riluzole—Hyperhidrosis—Cisplatin—esophageal cancer	0.000435	0.00147	CcSEcCtD
Riluzole—Asthma—Methotrexate—esophageal cancer	0.000434	0.00146	CcSEcCtD
Riluzole—Cardiac disorder—Capecitabine—esophageal cancer	0.000433	0.00146	CcSEcCtD
Riluzole—ABCG2—HIF-2-alpha transcription factor network—EP300—esophageal cancer	0.00043	0.00207	CbGpPWpGaD
Riluzole—Anorexia—Cisplatin—esophageal cancer	0.000429	0.00144	CcSEcCtD
Riluzole—CYP1A2—Arachidonic acid metabolism—PTGS1—esophageal cancer	0.000427	0.00206	CbGpPWpGaD
Riluzole—Pancreatitis—Methotrexate—esophageal cancer	0.000425	0.00143	CcSEcCtD
Riluzole—Angiopathy—Capecitabine—esophageal cancer	0.000423	0.00143	CcSEcCtD
Riluzole—Immune system disorder—Capecitabine—esophageal cancer	0.000421	0.00142	CcSEcCtD
Riluzole—Mediastinal disorder—Capecitabine—esophageal cancer	0.000421	0.00142	CcSEcCtD
Riluzole—Hypotension—Cisplatin—esophageal cancer	0.00042	0.00142	CcSEcCtD
Riluzole—SLC7A11—Hemostasis—HSPA5—esophageal cancer	0.000419	0.00202	CbGpPWpGaD
Riluzole—Chills—Capecitabine—esophageal cancer	0.000419	0.00141	CcSEcCtD
Riluzole—Arrhythmia—Capecitabine—esophageal cancer	0.000417	0.0014	CcSEcCtD
Riluzole—Abdominal discomfort—Methotrexate—esophageal cancer	0.000416	0.0014	CcSEcCtD
Riluzole—ABCG2—HIF-1-alpha transcription factor network—NOS2—esophageal cancer	0.000413	0.00199	CbGpPWpGaD
Riluzole—Alopecia—Capecitabine—esophageal cancer	0.000412	0.00139	CcSEcCtD
Riluzole—Pancytopenia—Methotrexate—esophageal cancer	0.000412	0.00139	CcSEcCtD
Riluzole—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00041	0.00138	CcSEcCtD
Riluzole—Mental disorder—Capecitabine—esophageal cancer	0.000409	0.00138	CcSEcCtD
Riluzole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000407	0.00196	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—PFN1—esophageal cancer	0.000406	0.00196	CbGpPWpGaD
Riluzole—Malnutrition—Capecitabine—esophageal cancer	0.000406	0.00137	CcSEcCtD
Riluzole—Neutropenia—Methotrexate—esophageal cancer	0.000406	0.00137	CcSEcCtD
Riluzole—Dysuria—Methotrexate—esophageal cancer	0.000406	0.00137	CcSEcCtD
Riluzole—Paraesthesia—Cisplatin—esophageal cancer	0.000404	0.00136	CcSEcCtD
Riluzole—Dyspnoea—Cisplatin—esophageal cancer	0.000401	0.00135	CcSEcCtD
Riluzole—Flatulence—Capecitabine—esophageal cancer	0.0004	0.00135	CcSEcCtD
Riluzole—Erectile dysfunction—Methotrexate—esophageal cancer	0.0004	0.00135	CcSEcCtD
Riluzole—CYP1A1—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000399	0.00193	CbGpPWpGaD
Riluzole—Dysgeusia—Capecitabine—esophageal cancer	0.000398	0.00134	CcSEcCtD
Riluzole—CYP1A1—Biological oxidations—ADH1B—esophageal cancer	0.000397	0.00192	CbGpPWpGaD
Riluzole—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000396	0.00134	CcSEcCtD
Riluzole—Back pain—Capecitabine—esophageal cancer	0.000393	0.00132	CcSEcCtD
Riluzole—SCN5A—Axon guidance—ACTB—esophageal cancer	0.000392	0.00189	CbGpPWpGaD
Riluzole—Decreased appetite—Cisplatin—esophageal cancer	0.000391	0.00132	CcSEcCtD
Riluzole—Muscle spasms—Capecitabine—esophageal cancer	0.000391	0.00132	CcSEcCtD
Riluzole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.00039	0.00188	CbGpPWpGaD
Riluzole—Pneumonia—Methotrexate—esophageal cancer	0.000389	0.00131	CcSEcCtD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1B1—esophageal cancer	0.000388	0.00187	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—CYP1B1—esophageal cancer	0.000388	0.00187	CbGpPWpGaD
Riluzole—CYP1A2—Tryptophan metabolism—CYP1B1—esophageal cancer	0.000388	0.00187	CbGpPWpGaD
Riluzole—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000388	0.00131	CcSEcCtD
Riluzole—Infestation NOS—Methotrexate—esophageal cancer	0.000387	0.0013	CcSEcCtD
Riluzole—Infestation—Methotrexate—esophageal cancer	0.000387	0.0013	CcSEcCtD
Riluzole—Depression—Methotrexate—esophageal cancer	0.000386	0.0013	CcSEcCtD
Riluzole—Pain—Cisplatin—esophageal cancer	0.000385	0.0013	CcSEcCtD
Riluzole—CYP1A2—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000385	0.00185	CbGpPWpGaD
Riluzole—Tremor—Capecitabine—esophageal cancer	0.000381	0.00128	CcSEcCtD
Riluzole—Stomatitis—Methotrexate—esophageal cancer	0.000377	0.00127	CcSEcCtD
Riluzole—Ill-defined disorder—Capecitabine—esophageal cancer	0.000377	0.00127	CcSEcCtD
Riluzole—Anaemia—Capecitabine—esophageal cancer	0.000375	0.00127	CcSEcCtD
Riluzole—CYP1A1—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000375	0.00181	CbGpPWpGaD
Riluzole—CYP1A2—Phase II conjugation—GSTO1—esophageal cancer	0.000374	0.0018	CbGpPWpGaD
Riluzole—SCN5A—SIDS Susceptibility Pathways—HIF1A—esophageal cancer	0.000373	0.0018	CbGpPWpGaD
Riluzole—SLC7A11—Cell surface interactions at the vascular wall—PIK3CA—esophageal cancer	0.000373	0.0018	CbGpPWpGaD
Riluzole—ABCG2—HIF-1-alpha transcription factor network—CREBBP—esophageal cancer	0.000371	0.00179	CbGpPWpGaD
Riluzole—Sweating—Methotrexate—esophageal cancer	0.000371	0.00125	CcSEcCtD
Riluzole—Feeling abnormal—Cisplatin—esophageal cancer	0.000371	0.00125	CcSEcCtD
Riluzole—CYP1A1—Biological oxidations—CYP26A1—esophageal cancer	0.000369	0.00178	CbGpPWpGaD
Riluzole—Haematuria—Methotrexate—esophageal cancer	0.000369	0.00124	CcSEcCtD
Riluzole—Malaise—Capecitabine—esophageal cancer	0.000366	0.00123	CcSEcCtD
Riluzole—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000366	0.00123	CcSEcCtD
Riluzole—CYP1A2—Tryptophan metabolism—CYP19A1—esophageal cancer	0.000365	0.00176	CbGpPWpGaD
Riluzole—Epistaxis—Methotrexate—esophageal cancer	0.000365	0.00123	CcSEcCtD
Riluzole—Vertigo—Capecitabine—esophageal cancer	0.000365	0.00123	CcSEcCtD
Riluzole—Syncope—Capecitabine—esophageal cancer	0.000364	0.00123	CcSEcCtD
Riluzole—CYP1A1—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000364	0.00176	CbGpPWpGaD
Riluzole—Leukopenia—Capecitabine—esophageal cancer	0.000364	0.00123	CcSEcCtD
Riluzole—CYP1A2—Arachidonic acid metabolism—CYP1B1—esophageal cancer	0.000363	0.00175	CbGpPWpGaD
Riluzole—Agranulocytosis—Methotrexate—esophageal cancer	0.000361	0.00122	CcSEcCtD
Riluzole—Palpitations—Capecitabine—esophageal cancer	0.000359	0.00121	CcSEcCtD
Riluzole—Loss of consciousness—Capecitabine—esophageal cancer	0.000357	0.0012	CcSEcCtD
Riluzole—Body temperature increased—Cisplatin—esophageal cancer	0.000356	0.0012	CcSEcCtD
Riluzole—Cough—Capecitabine—esophageal cancer	0.000354	0.00119	CcSEcCtD
Riluzole—Hypertension—Capecitabine—esophageal cancer	0.000351	0.00118	CcSEcCtD
Riluzole—Haemoglobin—Methotrexate—esophageal cancer	0.000349	0.00118	CcSEcCtD
Riluzole—Haemorrhage—Methotrexate—esophageal cancer	0.000347	0.00117	CcSEcCtD
Riluzole—Hepatitis—Methotrexate—esophageal cancer	0.000347	0.00117	CcSEcCtD
Riluzole—Arthralgia—Capecitabine—esophageal cancer	0.000346	0.00117	CcSEcCtD
Riluzole—Chest pain—Capecitabine—esophageal cancer	0.000346	0.00117	CcSEcCtD
Riluzole—Myalgia—Capecitabine—esophageal cancer	0.000346	0.00117	CcSEcCtD
Riluzole—Pharyngitis—Methotrexate—esophageal cancer	0.000345	0.00116	CcSEcCtD
Riluzole—Anxiety—Capecitabine—esophageal cancer	0.000345	0.00116	CcSEcCtD
Riluzole—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000343	0.00116	CcSEcCtD
Riluzole—CYP1A1—Biological oxidations—GSTO1—esophageal cancer	0.000343	0.00166	CbGpPWpGaD
Riluzole—Urinary tract disorder—Methotrexate—esophageal cancer	0.000343	0.00116	CcSEcCtD
Riluzole—Discomfort—Capecitabine—esophageal cancer	0.000342	0.00115	CcSEcCtD
Riluzole—Urethral disorder—Methotrexate—esophageal cancer	0.000341	0.00115	CcSEcCtD
Riluzole—CYP1A1—Metapathway biotransformation—GSTO1—esophageal cancer	0.000339	0.00163	CbGpPWpGaD
Riluzole—Dry mouth—Capecitabine—esophageal cancer	0.000338	0.00114	CcSEcCtD
Riluzole—CYP1A2—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000336	0.00162	CbGpPWpGaD
Riluzole—Confusional state—Capecitabine—esophageal cancer	0.000334	0.00113	CcSEcCtD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—RB1—esophageal cancer	0.000334	0.00161	CbGpPWpGaD
Riluzole—Oedema—Capecitabine—esophageal cancer	0.000332	0.00112	CcSEcCtD
Riluzole—Hypersensitivity—Cisplatin—esophageal cancer	0.000331	0.00112	CcSEcCtD
Riluzole—Infection—Capecitabine—esophageal cancer	0.000329	0.00111	CcSEcCtD
Riluzole—SCN5A—Developmental Biology—CFL1—esophageal cancer	0.000329	0.00159	CbGpPWpGaD
Riluzole—Erythema multiforme—Methotrexate—esophageal cancer	0.000328	0.00111	CcSEcCtD
Riluzole—Shock—Capecitabine—esophageal cancer	0.000326	0.0011	CcSEcCtD
Riluzole—Nervous system disorder—Capecitabine—esophageal cancer	0.000325	0.0011	CcSEcCtD
Riluzole—Eye disorder—Methotrexate—esophageal cancer	0.000325	0.00109	CcSEcCtD
Riluzole—Thrombocytopenia—Capecitabine—esophageal cancer	0.000325	0.00109	CcSEcCtD
Riluzole—Tachycardia—Capecitabine—esophageal cancer	0.000324	0.00109	CcSEcCtD
Riluzole—Asthenia—Cisplatin—esophageal cancer	0.000323	0.00109	CcSEcCtD
Riluzole—Cardiac disorder—Methotrexate—esophageal cancer	0.000322	0.00109	CcSEcCtD
Riluzole—Skin disorder—Capecitabine—esophageal cancer	0.000322	0.00109	CcSEcCtD
Riluzole—Hyperhidrosis—Capecitabine—esophageal cancer	0.00032	0.00108	CcSEcCtD
Riluzole—SCN5A—Developmental Biology—SOX2—esophageal cancer	0.000318	0.00153	CbGpPWpGaD
Riluzole—Anorexia—Capecitabine—esophageal cancer	0.000316	0.00107	CcSEcCtD
Riluzole—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000316	0.00152	CbGpPWpGaD
Riluzole—Angiopathy—Methotrexate—esophageal cancer	0.000315	0.00106	CcSEcCtD
Riluzole—ABCG2—Fluoropyrimidine Activity—TP53—esophageal cancer	0.000315	0.00152	CbGpPWpGaD
Riluzole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000314	0.00151	CbGpPWpGaD
Riluzole—Immune system disorder—Methotrexate—esophageal cancer	0.000314	0.00106	CcSEcCtD
Riluzole—Mediastinal disorder—Methotrexate—esophageal cancer	0.000313	0.00106	CcSEcCtD
Riluzole—Chills—Methotrexate—esophageal cancer	0.000312	0.00105	CcSEcCtD
Riluzole—SLC7A11—Hemostasis—ABL1—esophageal cancer	0.00031	0.0015	CbGpPWpGaD
Riluzole—CYP1A2—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.00031	0.00149	CbGpPWpGaD
Riluzole—Hypotension—Capecitabine—esophageal cancer	0.00031	0.00104	CcSEcCtD
Riluzole—Diarrhoea—Cisplatin—esophageal cancer	0.000308	0.00104	CcSEcCtD
Riluzole—Alopecia—Methotrexate—esophageal cancer	0.000307	0.00103	CcSEcCtD
Riluzole—SCN5A—SIDS Susceptibility Pathways—CREBBP—esophageal cancer	0.000305	0.00147	CbGpPWpGaD
Riluzole—Mental disorder—Methotrexate—esophageal cancer	0.000304	0.00103	CcSEcCtD
Riluzole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CRABP1—esophageal cancer	0.000303	0.00146	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—BAX—esophageal cancer	0.000303	0.00146	CbGpPWpGaD
Riluzole—Malnutrition—Methotrexate—esophageal cancer	0.000302	0.00102	CcSEcCtD
Riluzole—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000302	0.00102	CcSEcCtD
Riluzole—Insomnia—Capecitabine—esophageal cancer	0.0003	0.00101	CcSEcCtD
Riluzole—CYP1A2—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000299	0.00144	CbGpPWpGaD
Riluzole—Paraesthesia—Capecitabine—esophageal cancer	0.000298	0.001	CcSEcCtD
Riluzole—Dysgeusia—Methotrexate—esophageal cancer	0.000296	0.000998	CcSEcCtD
Riluzole—Dyspnoea—Capecitabine—esophageal cancer	0.000296	0.000996	CcSEcCtD
Riluzole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000295	0.00142	CbGpPWpGaD
Riluzole—Back pain—Methotrexate—esophageal cancer	0.000292	0.000986	CcSEcCtD
Riluzole—Dyspepsia—Capecitabine—esophageal cancer	0.000292	0.000984	CcSEcCtD
Riluzole—CYP1A2—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000291	0.00141	CbGpPWpGaD
Riluzole—CYP1A2—Phase II conjugation—GSTT1—esophageal cancer	0.00029	0.0014	CbGpPWpGaD
Riluzole—CYP1A2—Biological oxidations—ADH7—esophageal cancer	0.000289	0.00139	CbGpPWpGaD
Riluzole—Decreased appetite—Capecitabine—esophageal cancer	0.000288	0.000971	CcSEcCtD
Riluzole—ABCG2—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000287	0.00139	CbGpPWpGaD
Riluzole—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000286	0.000965	CcSEcCtD
Riluzole—Vomiting—Cisplatin—esophageal cancer	0.000286	0.000964	CcSEcCtD
Riluzole—Fatigue—Capecitabine—esophageal cancer	0.000286	0.000963	CcSEcCtD
Riluzole—Rash—Cisplatin—esophageal cancer	0.000284	0.000956	CcSEcCtD
Riluzole—Pain—Capecitabine—esophageal cancer	0.000283	0.000955	CcSEcCtD
Riluzole—Constipation—Capecitabine—esophageal cancer	0.000283	0.000955	CcSEcCtD
Riluzole—Dermatitis—Cisplatin—esophageal cancer	0.000283	0.000955	CcSEcCtD
Riluzole—Ill-defined disorder—Methotrexate—esophageal cancer	0.000281	0.000946	CcSEcCtD
Riluzole—SCN5A—Developmental Biology—ACTB—esophageal cancer	0.00028	0.00135	CbGpPWpGaD
Riluzole—CYP1A1—Biological oxidations—ALDH2—esophageal cancer	0.00028	0.00135	CbGpPWpGaD
Riluzole—Anaemia—Methotrexate—esophageal cancer	0.000279	0.000942	CcSEcCtD
Riluzole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—esophageal cancer	0.000279	0.00135	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—CTNNA1—esophageal cancer	0.000275	0.00133	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—esophageal cancer	0.000275	0.00132	CbGpPWpGaD
Riluzole—Feeling abnormal—Capecitabine—esophageal cancer	0.000273	0.000921	CcSEcCtD
Riluzole—Malaise—Methotrexate—esophageal cancer	0.000273	0.000919	CcSEcCtD
Riluzole—Vertigo—Methotrexate—esophageal cancer	0.000272	0.000916	CcSEcCtD
Riluzole—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000271	0.000914	CcSEcCtD
Riluzole—SLC7A11—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000271	0.00131	CbGpPWpGaD
Riluzole—Leukopenia—Methotrexate—esophageal cancer	0.000271	0.000912	CcSEcCtD
Riluzole—ABCG2—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.00027	0.0013	CbGpPWpGaD
Riluzole—Nausea—Cisplatin—esophageal cancer	0.000267	0.0009	CcSEcCtD
Riluzole—CYP1A1—Biological oxidations—GSTT1—esophageal cancer	0.000266	0.00128	CbGpPWpGaD
Riluzole—Cough—Methotrexate—esophageal cancer	0.000264	0.000889	CcSEcCtD
Riluzole—Urticaria—Capecitabine—esophageal cancer	0.000263	0.000888	CcSEcCtD
Riluzole—CYP1A1—Biological oxidations—CYP2A6—esophageal cancer	0.000263	0.00127	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—ABL1—esophageal cancer	0.000263	0.00127	CbGpPWpGaD
Riluzole—Abdominal pain—Capecitabine—esophageal cancer	0.000262	0.000883	CcSEcCtD
Riluzole—Body temperature increased—Capecitabine—esophageal cancer	0.000262	0.000883	CcSEcCtD
Riluzole—Convulsion—Methotrexate—esophageal cancer	0.000262	0.000883	CcSEcCtD
Riluzole—SCN5A—L1CAM interactions—EGFR—esophageal cancer	0.000261	0.00126	CbGpPWpGaD
Riluzole—SLC7A11—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.00026	0.00125	CbGpPWpGaD
Riluzole—Arthralgia—Methotrexate—esophageal cancer	0.000257	0.000868	CcSEcCtD
Riluzole—Myalgia—Methotrexate—esophageal cancer	0.000257	0.000868	CcSEcCtD
Riluzole—Chest pain—Methotrexate—esophageal cancer	0.000257	0.000868	CcSEcCtD
Riluzole—CYP1A1—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000257	0.00124	CbGpPWpGaD
Riluzole—ABCG2—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000256	0.00124	CbGpPWpGaD
Riluzole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000256	0.000862	CcSEcCtD
Riluzole—CYP1A2—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000255	0.00123	CbGpPWpGaD
Riluzole—Discomfort—Methotrexate—esophageal cancer	0.000254	0.000857	CcSEcCtD
Riluzole—CYP1A2—Biological oxidations—ADH1B—esophageal cancer	0.000253	0.00122	CbGpPWpGaD
Riluzole—ABCG2—HIF-1-alpha transcription factor network—EP300—esophageal cancer	0.000253	0.00122	CbGpPWpGaD
Riluzole—CYP1A1—Biological oxidations—PTGS1—esophageal cancer	0.000249	0.0012	CbGpPWpGaD
Riluzole—Confusional state—Methotrexate—esophageal cancer	0.000249	0.000839	CcSEcCtD
Riluzole—Anaphylactic shock—Methotrexate—esophageal cancer	0.000247	0.000832	CcSEcCtD
Riluzole—Infection—Methotrexate—esophageal cancer	0.000245	0.000826	CcSEcCtD
Riluzole—ABCG2—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000244	0.00118	CbGpPWpGaD
Riluzole—Hypersensitivity—Capecitabine—esophageal cancer	0.000244	0.000823	CcSEcCtD
Riluzole—Nervous system disorder—Methotrexate—esophageal cancer	0.000242	0.000816	CcSEcCtD
Riluzole—Thrombocytopenia—Methotrexate—esophageal cancer	0.000242	0.000814	CcSEcCtD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—CDKN1A—esophageal cancer	0.00024	0.00116	CbGpPWpGaD
Riluzole—Skin disorder—Methotrexate—esophageal cancer	0.00024	0.000808	CcSEcCtD
Riluzole—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000239	0.00115	CbGpPWpGaD
Riluzole—Hyperhidrosis—Methotrexate—esophageal cancer	0.000239	0.000804	CcSEcCtD
Riluzole—Asthenia—Capecitabine—esophageal cancer	0.000238	0.000802	CcSEcCtD
Riluzole—CYP1A2—Biological oxidations—CYP26A1—esophageal cancer	0.000235	0.00114	CbGpPWpGaD
Riluzole—Anorexia—Methotrexate—esophageal cancer	0.000235	0.000793	CcSEcCtD
Riluzole—Pruritus—Capecitabine—esophageal cancer	0.000235	0.000791	CcSEcCtD
Riluzole—ABCG2—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000234	0.00113	CbGpPWpGaD
Riluzole—ABCG2—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000234	0.00113	CbGpPWpGaD
Riluzole—CYP1A2—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000232	0.00112	CbGpPWpGaD
Riluzole—Hypotension—Methotrexate—esophageal cancer	0.000231	0.000777	CcSEcCtD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EP300—esophageal cancer	0.000228	0.0011	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—EP300—esophageal cancer	0.000228	0.0011	CbGpPWpGaD
Riluzole—Diarrhoea—Capecitabine—esophageal cancer	0.000227	0.000764	CcSEcCtD
Riluzole—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000225	0.000758	CcSEcCtD
Riluzole—SLC7A11—Hemostasis—NOS2—esophageal cancer	0.000224	0.00108	CbGpPWpGaD
Riluzole—Insomnia—Methotrexate—esophageal cancer	0.000223	0.000752	CcSEcCtD
Riluzole—Paraesthesia—Methotrexate—esophageal cancer	0.000222	0.000747	CcSEcCtD
Riluzole—Dyspnoea—Methotrexate—esophageal cancer	0.00022	0.000742	CcSEcCtD
Riluzole—Somnolence—Methotrexate—esophageal cancer	0.000219	0.000739	CcSEcCtD
Riluzole—Dizziness—Capecitabine—esophageal cancer	0.000219	0.000739	CcSEcCtD
Riluzole—CYP1A2—Biological oxidations—GSTO1—esophageal cancer	0.000219	0.00106	CbGpPWpGaD
Riluzole—Dyspepsia—Methotrexate—esophageal cancer	0.000217	0.000732	CcSEcCtD
Riluzole—CYP1A2—Metapathway biotransformation—GSTO1—esophageal cancer	0.000216	0.00104	CbGpPWpGaD
Riluzole—Decreased appetite—Methotrexate—esophageal cancer	0.000215	0.000723	CcSEcCtD
Riluzole—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000213	0.000718	CcSEcCtD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—RB1—esophageal cancer	0.000213	0.00103	CbGpPWpGaD
Riluzole—Fatigue—Methotrexate—esophageal cancer	0.000213	0.000717	CcSEcCtD
Riluzole—CYP1A1—Biological oxidations—CYP1B1—esophageal cancer	0.000212	0.00102	CbGpPWpGaD
Riluzole—Pain—Methotrexate—esophageal cancer	0.000211	0.000711	CcSEcCtD
Riluzole—Vomiting—Capecitabine—esophageal cancer	0.000211	0.00071	CcSEcCtD
Riluzole—CYP1A1—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000209	0.00101	CbGpPWpGaD
Riluzole—Rash—Capecitabine—esophageal cancer	0.000209	0.000704	CcSEcCtD
Riluzole—Dermatitis—Capecitabine—esophageal cancer	0.000209	0.000704	CcSEcCtD
Riluzole—SCN5A—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.000208	0.001	CbGpPWpGaD
Riluzole—Headache—Capecitabine—esophageal cancer	0.000208	0.0007	CcSEcCtD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000205	0.000987	CbGpPWpGaD
Riluzole—Feeling abnormal—Methotrexate—esophageal cancer	0.000203	0.000685	CcSEcCtD
Riluzole—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000202	0.00068	CcSEcCtD
Riluzole—SLC7A11—Hemostasis—CREBBP—esophageal cancer	0.000201	0.000969	CbGpPWpGaD
Riluzole—CYP1A1—Biological oxidations—CYP19A1—esophageal cancer	0.000199	0.000962	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—KDR—esophageal cancer	0.000199	0.00096	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—MYC—esophageal cancer	0.000199	0.00096	CbGpPWpGaD
Riluzole—Nausea—Capecitabine—esophageal cancer	0.000197	0.000664	CcSEcCtD
Riluzole—CYP1A1—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000197	0.000949	CbGpPWpGaD
Riluzole—Urticaria—Methotrexate—esophageal cancer	0.000196	0.000661	CcSEcCtD
Riluzole—Abdominal pain—Methotrexate—esophageal cancer	0.000195	0.000658	CcSEcCtD
Riluzole—Body temperature increased—Methotrexate—esophageal cancer	0.000195	0.000658	CcSEcCtD
Riluzole—SCN5A—Axon guidance—MET—esophageal cancer	0.000195	0.000939	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—esophageal cancer	0.000195	0.000939	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—esophageal cancer	0.000195	0.000939	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—ABL1—esophageal cancer	0.000187	0.000904	CbGpPWpGaD
Riluzole—Hypersensitivity—Methotrexate—esophageal cancer	0.000182	0.000613	CcSEcCtD
Riluzole—SCN5A—Developmental Biology—SMAD4—esophageal cancer	0.000182	0.000875	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—NOS3—esophageal cancer	0.00018	0.000867	CbGpPWpGaD
Riluzole—CYP1A2—Biological oxidations—ALDH2—esophageal cancer	0.000178	0.000861	CbGpPWpGaD
Riluzole—ABCG2—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.000178	0.000856	CbGpPWpGaD
Riluzole—Asthenia—Methotrexate—esophageal cancer	0.000177	0.000597	CcSEcCtD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—esophageal cancer	0.000175	0.000844	CbGpPWpGaD
Riluzole—Pruritus—Methotrexate—esophageal cancer	0.000175	0.000588	CcSEcCtD
Riluzole—SLC7A11—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000174	0.000839	CbGpPWpGaD
Riluzole—CYP1A2—Biological oxidations—GSTT1—esophageal cancer	0.00017	0.000819	CbGpPWpGaD
Riluzole—Diarrhoea—Methotrexate—esophageal cancer	0.000169	0.000569	CcSEcCtD
Riluzole—CYP1A2—Biological oxidations—CYP2A6—esophageal cancer	0.000168	0.000809	CbGpPWpGaD
Riluzole—CYP1A1—PPARA activates gene expression—CREBBP—esophageal cancer	0.000167	0.000805	CbGpPWpGaD
Riluzole—CYP1A2—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000164	0.00079	CbGpPWpGaD
Riluzole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CREBBP—esophageal cancer	0.000163	0.000788	CbGpPWpGaD
Riluzole—Dizziness—Methotrexate—esophageal cancer	0.000163	0.00055	CcSEcCtD
Riluzole—ABCG2—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000161	0.000777	CbGpPWpGaD
Riluzole—CYP1A2—Biological oxidations—PTGS1—esophageal cancer	0.000159	0.000767	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—BLVRB—esophageal cancer	0.000158	0.000764	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—SLC52A3—esophageal cancer	0.000158	0.000764	CbGpPWpGaD
Riluzole—Vomiting—Methotrexate—esophageal cancer	0.000157	0.000529	CcSEcCtD
Riluzole—Rash—Methotrexate—esophageal cancer	0.000156	0.000524	CcSEcCtD
Riluzole—Dermatitis—Methotrexate—esophageal cancer	0.000155	0.000524	CcSEcCtD
Riluzole—Headache—Methotrexate—esophageal cancer	0.000155	0.000521	CcSEcCtD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—esophageal cancer	0.000153	0.000738	CbGpPWpGaD
Riluzole—Nausea—Methotrexate—esophageal cancer	0.000147	0.000494	CcSEcCtD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—EP300—esophageal cancer	0.000146	0.000702	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—esophageal cancer	0.000146	0.000702	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—ERBB2—esophageal cancer	0.000142	0.000687	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—KDR—esophageal cancer	0.000142	0.000685	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—MET—esophageal cancer	0.000139	0.00067	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000138	0.000667	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—EP300—esophageal cancer	0.000137	0.00066	CbGpPWpGaD
Riluzole—CYP1A2—Biological oxidations—CYP1B1—esophageal cancer	0.000135	0.000652	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—SLC10A2—esophageal cancer	0.000135	0.000649	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—CA1—esophageal cancer	0.000135	0.000649	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—NOTCH1—esophageal cancer	0.000134	0.000645	CbGpPWpGaD
Riluzole—CYP1A2—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000133	0.000643	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.00013	0.000629	CbGpPWpGaD
Riluzole—CYP1A2—Biological oxidations—CYP19A1—esophageal cancer	0.000127	0.000613	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—MYC—esophageal cancer	0.000127	0.000612	CbGpPWpGaD
Riluzole—CYP1A2—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000125	0.000605	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—esophageal cancer	0.000124	0.000599	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—esophageal cancer	0.000124	0.000599	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—CA2—esophageal cancer	0.000123	0.000594	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—CREBBP—esophageal cancer	0.000121	0.000585	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000121	0.000582	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—PLCE1—esophageal cancer	0.000114	0.000552	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—ADH7—esophageal cancer	0.000114	0.000552	CbGpPWpGaD
Riluzole—CYP1A1—PPARA activates gene expression—EP300—esophageal cancer	0.000114	0.000548	CbGpPWpGaD
Riluzole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CREBBP—esophageal cancer	0.000113	0.000543	CbGpPWpGaD
Riluzole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—esophageal cancer	0.000111	0.000537	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—BLVRB—esophageal cancer	0.000107	0.000517	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—SLC52A3—esophageal cancer	0.000107	0.000517	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—ERBB2—esophageal cancer	0.000102	0.00049	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—PIK3CA—esophageal cancer	0.000101	0.000488	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—ADH1B—esophageal cancer	0.0001	0.000484	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—EGFR—esophageal cancer	9.87e-05	0.000476	CbGpPWpGaD
Riluzole—ABCG2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	9.82e-05	0.000473	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—TP53—esophageal cancer	9.79e-05	0.000472	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—TYMP—esophageal cancer	9.59e-05	0.000463	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	9.58e-05	0.000462	CbGpPWpGaD
Riluzole—ABCG2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	9.42e-05	0.000454	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—CYP26A1—esophageal cancer	9.33e-05	0.00045	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—CA1—esophageal cancer	9.11e-05	0.000439	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—SLC10A2—esophageal cancer	9.11e-05	0.000439	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—ALOX15—esophageal cancer	9.09e-05	0.000439	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	8.81e-05	0.000425	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—TPI1—esophageal cancer	8.67e-05	0.000418	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—GSTO1—esophageal cancer	8.67e-05	0.000418	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—CA2—esophageal cancer	8.33e-05	0.000402	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—ALDOB—esophageal cancer	8.32e-05	0.000401	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—EP300—esophageal cancer	8.26e-05	0.000398	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	8.14e-05	0.000393	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—GAPDH—esophageal cancer	8e-05	0.000386	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—CRABP1—esophageal cancer	7.93e-05	0.000383	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—ADH7—esophageal cancer	7.75e-05	0.000374	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—PLCE1—esophageal cancer	7.75e-05	0.000374	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	7.69e-05	0.000371	CbGpPWpGaD
Riluzole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—esophageal cancer	7.67e-05	0.00037	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	7.66e-05	0.000369	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—GNG7—esophageal cancer	7.55e-05	0.000364	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—ALDH2—esophageal cancer	7.07e-05	0.000341	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—EGFR—esophageal cancer	7.04e-05	0.00034	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—SLC52A3—esophageal cancer	6.83e-05	0.00033	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—BLVRB—esophageal cancer	6.83e-05	0.00033	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—ADH1B—esophageal cancer	6.79e-05	0.000328	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—GSTT1—esophageal cancer	6.73e-05	0.000324	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—CYP2A6—esophageal cancer	6.65e-05	0.000321	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—TYMP—esophageal cancer	6.49e-05	0.000313	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—CYP26A1—esophageal cancer	6.32e-05	0.000305	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—PTGS1—esophageal cancer	6.3e-05	0.000304	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—ENO1—esophageal cancer	6.3e-05	0.000304	CbGpPWpGaD
Riluzole—ABCG2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	6.3e-05	0.000304	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—PSME1—esophageal cancer	6.21e-05	0.0003	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—PSME2—esophageal cancer	6.21e-05	0.0003	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—ALOX15—esophageal cancer	6.15e-05	0.000297	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	6.11e-05	0.000295	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—TPI1—esophageal cancer	5.87e-05	0.000283	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—GSTO1—esophageal cancer	5.87e-05	0.000283	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—CA1—esophageal cancer	5.81e-05	0.00028	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—SLC10A2—esophageal cancer	5.81e-05	0.00028	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—ALDOB—esophageal cancer	5.63e-05	0.000271	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—GAPDH—esophageal cancer	5.42e-05	0.000261	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—CRABP1—esophageal cancer	5.37e-05	0.000259	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—CYP1B1—esophageal cancer	5.36e-05	0.000258	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—CA2—esophageal cancer	5.31e-05	0.000256	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	5.19e-05	0.00025	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—GNG7—esophageal cancer	5.11e-05	0.000246	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—CYP19A1—esophageal cancer	5.04e-05	0.000243	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—ADH7—esophageal cancer	4.94e-05	0.000238	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—PLCE1—esophageal cancer	4.94e-05	0.000238	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	4.88e-05	0.000235	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—ALDH2—esophageal cancer	4.79e-05	0.000231	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—HMOX1—esophageal cancer	4.6e-05	0.000222	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—GSTT1—esophageal cancer	4.55e-05	0.00022	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—CYP2A6—esophageal cancer	4.5e-05	0.000217	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	4.48e-05	0.000216	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—ABCB1—esophageal cancer	4.41e-05	0.000213	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—ADH1B—esophageal cancer	4.33e-05	0.000209	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—ENO1—esophageal cancer	4.27e-05	0.000206	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—PTGS1—esophageal cancer	4.27e-05	0.000206	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—PSME2—esophageal cancer	4.2e-05	0.000203	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—PSME1—esophageal cancer	4.2e-05	0.000203	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—TYMP—esophageal cancer	4.14e-05	0.0002	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—CYP26A1—esophageal cancer	4.03e-05	0.000194	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—ALOX15—esophageal cancer	3.92e-05	0.000189	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—TPI1—esophageal cancer	3.74e-05	0.000181	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—GSTO1—esophageal cancer	3.74e-05	0.000181	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	3.67e-05	0.000177	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—CYP1B1—esophageal cancer	3.63e-05	0.000175	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—ALDOB—esophageal cancer	3.59e-05	0.000173	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—GAPDH—esophageal cancer	3.45e-05	0.000167	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—CRABP1—esophageal cancer	3.42e-05	0.000165	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—CYP19A1—esophageal cancer	3.41e-05	0.000164	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—GNG7—esophageal cancer	3.26e-05	0.000157	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—HMOX1—esophageal cancer	3.11e-05	0.00015	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.05e-05	0.000147	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—ALDH2—esophageal cancer	3.05e-05	0.000147	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—ABCB1—esophageal cancer	2.99e-05	0.000144	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—CREBBP—esophageal cancer	2.95e-05	0.000142	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—GSTT1—esophageal cancer	2.9e-05	0.00014	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—CYP2A6—esophageal cancer	2.87e-05	0.000138	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.86e-05	0.000138	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—ENO1—esophageal cancer	2.72e-05	0.000131	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—PTGS1—esophageal cancer	2.72e-05	0.000131	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—PSME2—esophageal cancer	2.68e-05	0.000129	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—PSME1—esophageal cancer	2.68e-05	0.000129	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—NOS3—esophageal cancer	2.64e-05	0.000127	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—PTGS2—esophageal cancer	2.42e-05	0.000116	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.34e-05	0.000113	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—CYP1B1—esophageal cancer	2.31e-05	0.000112	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.26e-05	0.000109	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—CYP19A1—esophageal cancer	2.17e-05	0.000105	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—EP300—esophageal cancer	2.01e-05	9.69e-05	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—CREBBP—esophageal cancer	2e-05	9.63e-05	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—HMOX1—esophageal cancer	1.98e-05	9.57e-05	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.95e-05	9.39e-05	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—ABCB1—esophageal cancer	1.9e-05	9.19e-05	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—NOS3—esophageal cancer	1.79e-05	8.62e-05	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—PTGS2—esophageal cancer	1.63e-05	7.88e-05	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—PIK3CA—esophageal cancer	1.49e-05	7.17e-05	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.44e-05	6.95e-05	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—EP300—esophageal cancer	1.36e-05	6.56e-05	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—CREBBP—esophageal cancer	1.27e-05	6.14e-05	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—NOS3—esophageal cancer	1.14e-05	5.5e-05	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—PTGS2—esophageal cancer	1.04e-05	5.03e-05	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—PIK3CA—esophageal cancer	1.01e-05	4.85e-05	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—EP300—esophageal cancer	8.67e-06	4.18e-05	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—PIK3CA—esophageal cancer	6.41e-06	3.09e-05	CbGpPWpGaD
